Periorbital Changes associated with Topical Prostaglandins Analogues in a Hispanic Population.
This study was approved by the Institutional Review Board of University of Puerto Rico School of Medicine. An analytical cross sectional study was conducted focused on a single interview/interaction with the study subjects. For this study, a QOL questionnaire was developed (Table 1), which was validated by six faculty members of the University of Puerto Rico with specialties in general ophthalmology, cornea, glaucoma and retina. The questionnaire includes questions about the changes in the eye during the PA use. A reliability statistic Cronbach's was performed and the alpha values are all satisfactory, scoring 1.0. In order for those scores to be considered reliable, the measure would be equal or greater than 0.60 (13).
A total of fourteen patients participated in the study (ten women and four men). Their ages ranged from twenty-six years old to seventy-eight years old. At the time of participation all patients in the study are Hispanic and living in Puerto Rico (Table 2). The inclusion criterion for the study was for patients to have used or currently using a PA eye drop (Bimatoprost 0.01%, Latanoprost 0.005%, or Travoprost 0.004%) limited to one eye (previously prescribed by an Ophthalmologist other than the PI) and had to be older than 21 years of age. Patients who had used PA in both eyes at any given time in the past were excluded from the study.
All patients underwent a single full Oculoplastic evaluation by two physicians; one of them was blinded on patient medical history and was assessed for PA side effects such as deepening of the upper eyelid sulcus, periorbital skin pigmentation, eyelash elongation, foreign body sensation, and dry eye symptoms. After evaluation, each study subject was asked to answer a self-reported QOL questionnaire to aid in measuring the effect in QOL. The survey comprised of eight questions, each had three possible answers [never/rarely (0 points), sometimes (1 point), frequently/all-the-time (2 points)], and however, only one answer per question could be selected. Points for all questions were added for each patient and this was considered their "QOL index". A mean QOL index was calculated for each PA. Items in the questionnaire were evaluated according to the Fisher's exact test. P-values less than 0.05 were considered to be statistically significant. Computing the patients' responses to all questions created the QOL index. A Kruskal-Wallis test was conducted to evaluate the PA complications and their effect in the patients' QOL.
Two out of fourteen patients (14.3%) were noted to have periocular skin pigmentation in the affected eye (Table 3). Eleven out of fourteen patients (78.6%) were noted to have thicker, longer and darker eyelashes on the eye using PA eye drops. A comparison by the examiner of eye using the PA eye drop vs. the eye that did not use the drops resulted in: four patients having used Bimatoprost (28.6%), seven patients having used Latanoprost (50%) and three patients having used Travoprost (21.4%) (Table 3).
Of those who used Bimatoprost, one (25%) showed periorbital skin pigmentation, three (75%) had thicker, longer and darker eyelashes. The study subjects who are using or used Latanoprost, one (14.3%) had periorbital skin pigmentation; five (71.4%) had thicker, longer and darker eyelashes. Those who used Travoprost none (0%) showed periorbital skin pigmentation and three (100%) showed thicker, longer and darker eyelashes (Table 3).
After evaluating the clinical eye related effects of PA, periorbital skin pigmentation was observed in two PA; one patient that uses Bimatoprost (25%) and two patients that use Latanoprost (28.5%). Only one patient (25%) presented sunken eyes and uses Bimatoprost. Eyelashes' changes are observed in the three PA, where three patients used Bimatoprost (75%), five patients used Latanoprost (71.4%) and three patients used Travoprost (100%).
However, this difference was not statistically significant. In terms of spontaneous blinking one patient that uses Bimatoprost (25%) presented incomplete spontaneous blinking. The Bell's phenomenon is normal in nine patients, where four are Bimatoprost user (100%), four are Latanoprost users (57.1%) and one patient is Travoprost user (33%). In reviewing the PA effects on lid margin, telangiectasia is present in two Bimatoprost users (50%), one Latanoprost user (14.3%) and in one Travoprost user (33%). In respect to conjunctiva, one Latanoprost user had conjuctivochalasis. A single patient from the Bimatoprost and the Latanoprost group presented with injected sclera. Fluorescein staining was seen in three, five and one patients from the bimatoprost, latanoprost and travoprost groups respectively.
Overall, a greater percentage of patients in the Bimatoprost group noticed a change in the size/shape of their eyes when compared to the latanoprost group, while in the travoprost group only one patient (33%) complained (Table 4). The Bimatoprost group disliked how their eyes looked the most (100% of the patients), 57.1% of Latanoprost users and Travoprost the least with 33%. 71.4% of Latanoprost users complained of dry eye symptoms, 67% and 50% of the Travoprost and Bimatoprost groups respectively, this correlates directly with the foreign body sensation complaints. Increased need to blink was noticed more on the Travoprost group (33%), followed by Bimatoprost (25%) and Latanoprost (14.3%) users. Travoprost users (67%) noticed burning sensation more than their Bimatoprost (50%) and Latanoprost (42.9%) counterparts. Secretions and eyelid crusting were reported by 50% of the Bimatoprost users. Only one of the Latanoprost users reported sticky eyes (14.3%). A mean of QOL effect was calculated for each PA. Bimatoprost eye drops were noted to have the most significant effect in QOL as evidenced by a QOL mean of 3.5, compared to 2.0 in the Travoprost group and 2.14 in the Latanoprost users (Table 5).
In this group of Hispanic patients, we present evidence that chronic use of PA eye drops can be linked to periorbital changes previously described in the literature. Given the fact that our patients used PA unilaterally, they were more likely to notice changes in the size/shape of their eyes. The most common side effect noticed in our study population was eyelash elongation, changes in the size/shape of their eyes, and dry eye symptoms. Out of these patients, all except for four reported that they were not happy with the appearance of their eyes.
The quality of life questionnaire showed that in general, the Bimatoprost side effects had the most negative impact in quality of life, followed by the Latanoprost and lastly the Travoprost; however, these differences are not of statistical significance (Table 5). Bimatoprost users noted a greater difference in the size/shape of their eyes, followed by Latanoprost users, and lastly the Travoprost group. None of the Bimatoprost users liked how their eyes looked, while the Latanoprost users were the most satisfied group in terms of how their eyes looked. However, the Bimatoprost group reported having less dry eye symptoms and foreign body sensation than the Latanoprost group. The Latanoprost patients complained the most of having dry-eye symptoms, foreign body sensation, while the Travoprost group noticed the need to blink in order to see well, and burning sensation more frequently. Latanoprost users complained the least of the need to blink in order to see well. The Bimatoprost group complained the most of having secretions, while the other two groups had no complaints. The Bimatoprost group also complained the most about eyelid crusting, followed by the Latanoprost group, while there were no complaints in the Travoprost users.
There are few studies that evaluate the QOL in patients using PA for glaucoma. Our study is unique in that it studies a Hispanic population; the focus of effect in QOL embraces dry eye symptoms as well as periocular side effects. To our knowledge, this is the first study that evaluates PAP using the subjects' contralateral eye as a control group.
After evaluating the effect on QOL of each PA, we didn't find a statistically significant difference. However, as evidenced by mean QOL, the Bimatoprost group QOL was more affected than the other two groups, followed by the Latanoprost group and lastly the Travoprost group.
Several studies have reported that stopping glaucoma treatment with PA due to their side effects is not common. However, Reardon and coworkers (14) found that compared with Latanoprost, those using Bimatoprost were 38% more likely to discontinue/change treatment and those being treated with Travoprost were 36% more likely to discontinue/ change treatment. This behavior might be explained by our mean QOL, as previously described those in the Bimatoprost group had a higher mean QOL followed by Travoprost users. A more recent study by Campbell and his team (15) compared adherence in patients using Bimatoprost 0.01% vs Bimatoprost 0.03%, and found that those using the lower dose PA had higher adherence to treatment, this might suggest a dose dependent effect on mean QOL as suggested by lack of adherence, however further studies are needed to prove this hypothesis. Interestingly, Quaranta and company (16) studied seventy-five eyes using Travoprost but only five eyes discontinued the medication due to side effects. Measurement of QOL in these patients is important as it can help establish parameters in regards to discontinuing PA treatment in patients experiencing severe side effects negatively affecting QOL.
The results in this study were of no statistical significance as noted on thep values for the study data. Possible contributing factors for this are the low number of subjects used in the study, different number of subjects per study group, different duration of treatment with PA for each subject, among other possible causes. Nonetheless, we believe this data will serve as a guide for the scientific community for further studies.
(1.) Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical Bimatoprost therapy. Optom Vis Sci 2004;81:574-7
(2.) Kucukevcilioglu M, Bayer A, Uysal Y Altinsoy HI. Prostaglandin associated periorbitopathy in patients using Bimatoprost, Latanoprost and Travoprost. Clin Experiment Ophthalmol 2014;42:126-31.
(3.) Hollo G. The side effects of the prostaglandin analogues. Expert opinion on drug safety 2007;6:45-52.
(4.) Alm A, Grierson I, Shields MB: Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53:S93-S105.
(5.) Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost-induced to periocular skin changes in Caucasians. Ophthalmology 2006;113:1961-7.
(6.) Filippopoulos T, Paula JS, Torun N, et al. Periorbital changes associated with topical Bimatoprost. Ophthal Plast Reconstr Surg 2008;24:302-7.
(7.) Inoue K, Shiokawa M, Higa R, Sugahara M, Soga T, Wakakura M, Tomita G. Adverse periocular reactions to five types of prostaglandin analogs. Eye 2012;26:1465-72.
(8.) Linden C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging 1999;14:387-98.
(9.) Takahashi GI, Otori Y Urashima M, Kuwayama Y. Evaluation of Quality of Life in Glaucoma Patients and its Relationship With Visual Function. Journal of Glaucoma 2016;25:150-6.
(10.) Camp A, Wellik SR, Tzu JH, Feuer W, Arheart KL, Sastry A, Galor A. Dry eye specific quality of life in veterans using glaucoma drops. Contact Lens & Anterior Eye: the journal of the British Contact Lens Association 2015;38:220-5.
(11.) Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Ocular Hypotensive
Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma. Archives of Ophthalmology 2002;120:701-13.
(12.) Cook C, Foster P. Epidemiology of glaucoma: what's new? Canadian Journal of Ophthalmology 2012;47:223-6.
(13.) Wasserman JD, Bracken BA. Psychometric characteristics of assessment procedures. In: Graham JR, Naglieri JA (eds) Handbook of psychology: assessment psychology, vol. 10. John Wiley and Sons, Inc., Hoboken, NJ, 2003, pp. 3-66.
(14.) Reardon G, Schwartz G, Mozaffari E. Patient Persistency with ocular prostaglandin therapy: A population-based, retrospective study. Clinical Therapeutics 2003;25:1172-85.
(15.) Campbell JH, Schartz G, Labounty B, Kowalski J, Patel VD. Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Current medical research and opinion 2013;29:1201-9
(16.) Quaranta L, Riva I, Katsasnos A, Floriani I, Centofanti M, Konstas A. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clinical Ophthalmology 2015;9:633-43.
Ferdinand Rodriguez-Agramonte, MD; Juan Carlos Jimenez, MD; Jose Raul Montes, MD, FACS, FACCS
Department of Ophthalmology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Address correspondence to: Ferdinand Rodriguez, MD, PO Box 365067 San Juan PR 00936-5067. Email: email@example.com
Table 1. Quality of life questionnaire Never or Sometimes (1) rarely (0) Have you noticed any difference in the shape and/or size of your eyes? Do you like how your eyes look? Do you feel your eyes dry? Do you feel the need to blink to see more clearly? Do you have foreign body sensation? Do you feel a burning sensation in your eyes? Do you have secretions or tearing? Do you have sticky eyes in the morning? Frequently or always (2) Have you noticed any difference in the shape and/or size of your eyes? Do you like how your eyes look? Do you feel your eyes dry? Do you feel the need to blink to see more clearly? Do you have foreign body sensation? Do you feel a burning sensation in your eyes? Do you have secretions or tearing? Do you have sticky eyes in the morning? Table 2. Patient demographics Variable Categories Frequency (%) Sex Female 10 (71) Male 4 (29) Race Black 5 (36) Hispanic 8 (57) White 1 (7) Education Level 7-12 yrs. 2 (14) >12 yrs. 12 (86) Table 3. Adverse effects in the treated eyes Prostaglandins (%) Bimatoprost 0.01% Ptosis None 3(75) Mild 1(25) Periorbital Skin Color No 3(75) Yes 1(25) Periorbital Fat Show No -- Severe 4(100) Eyelashes No Change 1(25) Thicker, Darker, Longer 3(75) Spontaneous Blinking Normal 2 (50) Average 1(25) Incomplete 1(25) Bell's phenomenon Present 4(100) Abnormal -- Absent -- Lids margin Meibomian -- Meibomian and 2(50) Telangiectasia Normal 1(25) Telangiectasia 1(25) Conjunctiva Conjuctivochalasis -- Inflammation (Injected) 1(25) Normal 3(75) Cornea Normal 1(25) Fluorescein Staining 3(75) Iris Change 1 (25) Same 3 (75) Prostaglandins (%) Latanoprost 0.005% Ptosis None 7 (100) Mild -- Periorbital Skin Color No 6(86) Yes 1 (14) Periorbital Fat Show No 2(29) Severe 5(71) Eyelashes No Change 2(29) Thicker, Darker, Longer 5(71) Spontaneous Blinking Normal 6(86) Average 1(14) Incomplete -- Bell's phenomenon Present 3 (43) Abnormal 3 (43) Absent 1(14) Lids margin Meibomian 3(43) Meibomian and 1(14) Telangiectasia Normal 2(29) Telangiectasia 1(14) Conjunctiva Conjuctivochalasis 1 (14) Inflammation (Injected) -- Normal 6 (86) Cornea Normal 3(43) Fluorescein Staining 4(57) Iris Change 4 (57) Same 3 (43) Prostaglandins (%) Travoprost 0.004% Ptosis None 2 (67) Mild 1 (33) Periorbital Skin Color No 3(100) Yes -- Periorbital Fat Show No 1(33) Severe 2(67) Eyelashes No Change -- Thicker, Darker, Longer 3(100) Spontaneous Blinking Normal 2(67) Average 1(33) Incomplete -- Bell's phenomenon Present 1(33) Abnormal 1(33) Absent 1(33) Lids margin Meibomian 1(33) Meibomian and -- Telangiectasia Normal 1(33) Telangiectasia 1(33) Conjunctiva Conjuctivochalasis -- Inflammation (Injected) -- Normal 3(100) Cornea Normal 2(67) Fluorescein Staining 1(33) Iris Change -- Same 3 (100) P value * Ptosis None 0.231 Mild Periorbital Skin Color No 1.00 Yes Periorbital Fat Show No 0.538 Severe Eyelashes No Change 1.00 Thicker, Darker, Longer Spontaneous Blinking Normal 0.691 Average Incomplete Bell's phenomenon Present 0.334 Abnormal Absent Lids margin Meibomian 0.799 Meibomian and Telangiectasia Normal Telangiectasia Conjunctiva Conjuctivochalasis 0.769 Inflammation (Injected) Normal Cornea Normal 0.790 Fluorescein Staining Iris Change 0.371 Same * Fisher Exact Test Table 4. Self reported adverse effects in quality of life Prostaglandins Bimatoprost 0.01% Change in the eye's shape/size Never or rare -- Sometimes/always 4(100) Like how the eyes look Never or rare 4(100) Sometimes/always -- Dry eye Never or rare 2(50) Sometimes/always 2(50) Need to blink many times Never or rare 3(75) Sometimes/always 1(25) Foreign body sensation Never or rare 3(75) Sometimes/always 1(25) Burning sensation Never or rare 2(50) Sometimes/always 2(50) Feeling secretions Never or rare 2(50) Sometimes/always 2(50) Sticky eye Never or rare 2(50) Sometimes/always 2(50) Prostaglandins Latanoprost 0.005% Change in the eye's shape/size Never or rare 2 (29) Sometimes/always 5 (71) Like how the eyes look Never or rare 4 (57) Sometimes/always 3 (43) Dry eye Never or rare 2 (29) Sometimes/always 5 (71) Need to blink many times Never or rare 6 (86) Sometimes/always 1 (14) Foreign body sensation Never or rare 4 (57) Sometimes/always 3 (43) Burning sensation Never or rare 4 (57) Sometimes/always 3 (43) Feeling secretions Never or rare 7 (100) Sometimes/always -- Sticky eye Never or rare 6 (86) Sometimes/always 1 (14) Prostaglandins Travoprost 0.004% Change in the eye's shape/size Never or rare 2(67) Sometimes/always 1(33) Like how the eyes look Never or rare 2(67) Sometimes/always 1(33) Dry eye Never or rare 1(33) Sometimes/always 2(67) Need to blink many times Never or rare 2(67) Sometimes/always 1(33) Foreign body sensation Never or rare 2(67) Sometimes/always 1(33) Burning sensation Never or rare 1(33) Sometimes/always 2(67) Feeling secretions Never or rare 3(100) Sometimes/always -- Sticky eye Never or rare 3(100) Sometimes/always -- P value * Change in the eye's shape/size Never or rare 0.168 Sometimes/always Like how the eyes look Never or rare 0.357 Sometimes/always Dry eye Never or rare 0.790 Sometimes/always Need to blink many times Never or rare 1.00 Sometimes/always Foreign body sensation Never or rare 1.00 Sometimes/always Burning sensation Never or rare 1.00 Sometimes/always Feeling secretions Never or rare 0.099 Sometimes/always Sticky eye Never or rare 0.365 Sometimes/always * Fisher's exact test Table 5. Comparison of quality of life mean by Prostaglandins Patients Mean Minimum Maximum of QOL Bimatoprost 0.01% 4 3.50 1.00 6.00 Latanoprost 0.005% 7 2.14 0.00 4.00 Travoprost 0.004% 3 2.00 0.00 3.00 Total 14 2.50 0.00 6.00 Kruskal- P Value * Wallis * Bimatoprost 0.01% 1.361 0.526 Latanoprost 0.005% Travoprost 0.004% Total * Kruskal-Wallis test Figure 1. Index of quality of life by prostaglandin analogues Prostaglandins Bimatoprost 0.01% 3.50 Latanoprost 0.005% 2.14 Travopost 0.004% 2.00 Note: Table made from line graph.
|Printer friendly Cite/link Email Feedback|
|Author:||Rodriguez-Agramonte, Ferdinand; Jimenez, Juan Carlos; Montes, Jose Raul|
|Publication:||Puerto Rico Health Sciences Journal|
|Date:||Dec 1, 2017|
|Previous Article:||Clinical Profile of Patients with Psychogenic Non-epileptic Seizures in Puerto Rico.|
|Next Article:||Gene Expression, and Fatigue in Puerto Rican Men during Radiotherapy for Prostate Cancer: an Exploratory Study.|